IN8bio was founded with the mission of developing novel therapies to address cancer. The company focuses on the development of cellular therapies using gamma-delta T cells, the “unconventional” T cell and is advancing a pipeline of autologous, allogeneic and genetically modified product candidates for both liquid and solid tumors.